Ibandronate (Boniva IV)

OFFICE ADMINISTRATION

Indications for Prior Authorization:

  • Osteoporosis

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

  • Padget’s disease
  • Prevention of Osteoporosis

All of the following must be met:

  • Treatment of osteoporosis in postmenopausal woman
  • T-score is more than -2.5 SD below the young normal OR the presence or history of osteoporotic fracture; AND
  • Intolerable side effects with two of the following oral bisphosphanates: Fosamax or Actonel and Boniva; OR
  • Boniva injection should be reserved for patients with intrinsic swallowing mechanism defect who cannot take any oral formulary of medication

Dosing:

  • For Osteoporosis Treatment
  • The recommended dose is 3 mg every three months administered over a period of 15 to 30 seconds

 

Last review date: December 2, 2013

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.